ANXA2 and lung carcinoma: ANXA2 silencing significantly decreases the mRNA and protein expression of Bcl-1 and promotes apoptosis in osteosarcoma through the AKT signalling pathway and, in lung cancer, by the activity of p53 (Huang et al., 2008; Pan et al., 2018).